secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0000950170-24-119270
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK appoints former HHS ASPR Robert Kadlec to board
----------------------------------------------------

- Dr. Robert Kadlec elected Class II director effective Oct. 30, 2024; term expires at 2026 annual meeting.
- Previously served as HHS Assistant Secretary for Preparedness and Response and co-conceived Operation Warp Speed.
- Will serve on Corporate Governance and Nominating Committee; granted option for 41,745 shares vesting over 3 years.
- Expertise in biodefense and pandemic preparedness aligns with MiNK's iNKT cell therapy focus on ARDS and infectious diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000095017024119270/0000950170-24-119270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000095017024119270/inkt-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-119270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer